摘要
免疫检查点抑制剂在中国获批时间较短,真实世界的临床数据尚处于收集阶段,国内程序细胞死亡蛋白1(programmed death-1,PD-1)治疗相关不良反应的报道罕见。笔者报道1例Pembrolizumab输注过程中出现低血压,血压恢复后成功输注的案例,希望能为免疫检查点抑制剂的应用提供参考,为患者提供最大的临床获益。
Immunological checkpoint inhibitors have been approved for a short period of time in China,and realworld clinical data are still in the collection stage.Reports of domestic programmed death-1(PD-1)treatment-related adverse reactions are rare.The author reported a case of hypotension in the process of Pembrolizumab infusion and successful infusion after blood pressure recovery,hoping to provide reference for the application of immunological checkpoint inhibitors,to provide patients with the greatest clinical benefit.
作者
宋鹏
张晓彤
张力
Peng SONG;Xiaotong ZHANG;Li ZHANG(Department of Respiratory Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100730,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2019年第11期738-740,共3页
Chinese Journal of Lung Cancer
